Generic Drug Firm Asks High Court To Nix Stay In Novartis MS Drug Patent Spat
WASHINGTON, D.C. — Novartis Pharmaceuticals Corp. is not entitled to the stay of a Federal Circuit U.S. Court of Appeals mandate that held a patent for multiple sclerosis (MS) treatment to...To view the full article, register now.
Already a subscriber? Click here to view full article